Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LY450139: Tolerability and Biomarker Assessment in Subjects With Mild to Moderate Alzheimer's Disease

NCT00244322 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00244322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00244322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LY450139: Tolerability and Biomarker Assessment in Subjects With Mild to Moderate Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2005
Completion date
December 31, 2006
Enrollment
45
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease